|
Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes
|
Mar 2014
|
Expert Rev Anticancer Ther
|
myelodysplastic syndromes (MDS)
|
|
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
|
Jan 2018
|
Am J Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
|
Mar 2014
|
Biol Blood Marrow Transplant
|
myelodysplastic syndromes (MDS)
|
|
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia
|
Jun 2020
|
Haematologica
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia
|
Dec 2014
|
Hematology Am Soc Hematol Educ Program
|
myelodysplastic syndromes (MDS)
|
|
Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia
|
Dec 2014
|
Hematology Am Soc Hematol Educ Program
|
aplastic anemia
|
|
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes
|
Apr 2023
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
|
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: is eculizumab indicated?
|
Jul 2012
|
Ann Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Thrombosis in paroxysmal nocturnal hemoglobinuria.
|
Apr 2013
|
Blood
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Thrombopoiesis-stimulating agents and myelodysplastic syndromes
|
Feb 2015
|
Br J Haematol
|
myelodysplastic syndromes (MDS)
|
